The investment saw participation from Eli Lilly and Company alongside principals of Scopia Capital Management. Frank Fazio, President and CEO of Amplifica, noted that the capital injection validates the company's scientific approach to reactivating dormant hair follicles. Unlike existing daily-use medications such as finasteride or minoxidil, which primarily focus on slowing hair loss, Amplifica’s candidates are designed to stimulate new growth through distinct molecular signaling mechanisms.

Androgenetic alopecia impacts approximately 80 million people in the United States, yet current treatment options often face hurdles regarding patient compliance and limited efficacy. Co-Founder and Executive Chairman Wajdie Ahmad stated that the company is running multiple development programs in parallel to increase the probability of clinical success. The firm plans to utilize these proceeds to transition its nature-inspired portfolio into advanced clinical development, targeting regulatory milestones for its injectable product pipeline.